Posts tagged EU
Ladenburg starts AIT Therapeutics at buy

Ladenburg Thalmann launched coverage of AIT Therapeutics (NASDAQ:AITB) with a “buy” rating and $17 price target. The stock closed at $5.50 on Aug. 4.

Read More
Ladenburg starts Albireo Pharma at buy

Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15.

Read More
Leerink starts Spark Therapeutics at OP

Leerink initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with an “outperform” rating and $85 price target. The stock closed at $63.06 on Jan. 8.

Read More
Vital Therapies updates Phase 3 trial

Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.

Read More
IntelGenx, RedHill license Rizaport in Korea

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea.

Read More
Wainwright starts Summit Therapeutics at buy

H.C. Wainwright initiated coverage of Summit Therapeutics (NASDAQ:SMMT) with a “buy” rating and $26 price target. The stock closed at $5.50 on Thursday.

Summit has two de-risked assets, with billion-dollar potential, and is conducting clinical programs focused on two genetic diseases: Duchenne muscular dystrophy (DMD) and Clostridium difficile infections (CDI).

Read More
pSivida names Nancy Lurker as CEO

pSivida (NASDAQ:PSDV) has appointed Nancy Lurker as president, CEO and a member of the board, succeeding Paul Ashton, who has resigned to pursue other interests.

Ms. Lurker, a seasoned healthcare executive, brings strong leadership and extensive experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global drug launches. From 2008 to 2015, she served as president, CEO and a director of PDI.

Read More
Stifel ups Aerie Pharma price target to $50

Stifel raised it price target for Aerie Pharmaceuticals (NASDAQ:AERI) to $50 from $40 after the company’s Roclatan eye drop hit all its endpoints with clinically meaningful results in a Phase 3 trial. The stock closed at $21.13 on Wednesday.

Analyst Annabel Samimy writes that the 90-day primary efficacy readout of the MERCURY-1 trial demonstrated statistically significant lowering of intraocular pressure (IOP) of Roclatan over its Rhopressa and latanoprost components.

Read More
Vital Therapies updates Phase 3 trial

In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company's Phase 3 trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.  

There are now 24 sites open for enrollment in the U.S and EU. The company expects to announce topline results in mid-2018.

Read More
Dipexium receives Locilex patent in EU

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU.

The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. The issued patent has an expiry date in June 2033.

Read More
Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.

“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.

Read More
Maxim downgrades Radius Health to sell

Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday.

“At the current valuation, we believe that Radius is back to an overvalued state,” writes analyst Jason McCarthy.

Read More
Dipexium, Tandem Diabetes make Feltl Best Ideas list

Dipexium Pharmaceuticals (NASDAQ:DPRX) and Tandem Diabetes (NASDAQ:TNDM) have made Feltl & Co.’s Best Ideas list for the second half this year.

Analyst Ben Haynor writes that top-line data for Dipexium’s two Phase 3 studies should be released in the next six-to-10 weeks, “which we believe will be positive,” based on trials conducted by Magainin Pharmaceuticals in the late 1990s and the design of Dipexium’s studies, which compare Locilex versus placebo cream.

Read More
Canaccord ups GenMark price target to $10.50

Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday.

After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by the end of June.

Read More
Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.

Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.

Read More
Leerink starts Proteostasis Therapeutics at outperform

Leerink Partners has initiated coverage of Proteostasis Therapeutics (NASDAQ: PTI) with an “outperform” rating and $13 price target in 12 months. The stock closed at $5.56 on Friday.

Proteostasis’ lead candidate, PTI-428, is designed to work as an “amplifier,” which can work additively with Orkambi (corrector/potentiator combination) to increase functioning cystic fibrosis transmembrane conductance regulator (CFTR) on the cell membrane.

Read More